Sodium nitroprusside: pharmacology, toxicology and therapeutics.
Sodium nitroprusside is a potent, effective, and readily reversible direct vasodilating agent. It is broken down by hemoglobin into cyanide, which is in part detoxified by liver and kidney to thiocyanate. Some cyanide, especially in nitroprusside- "resistant" individuals who need large amounts of the drug, appears to remain free to cause cyanide poisoning. Patients requiring inordinate amounts probably should not continue to receive the drug, although maximum dosage limits for long-term therapy are not established. Blood thiocyanate levels do not indicate the extent to which free cyanide is limiting oxygen utilization in essential tissue, nor do blood cyanide levels. Metabolic acidosis, elevated lactate levels, elevated lactate/pyruvate ratios, and elevated mixed venous blood oxygen content are at present the best indications of the presence of cyanide poisoning during nitroprusside administration. Nitroprusside appears useful for induction of hypotension during surgery, and for treatment of hypertensive emergencies from all causes, although continuance for more than a few days is probably unwise. The reductions of cardiac afterload and ventricular filling pressure by nitroprusside appear useful in treatment of severe myocardial failure or infarction, but studies of myocardial cyanide toxicity are needed before complete acceptance of this therapy is warranted. Initial dose rates between 0.5 and 1.5 mug/kg/min are recommended only as starting points for very careful titration. Total projected intra-operative dosage should be calculated as quickly as possible and should not exceed 3-3.5 mg/kg. It is hoped that future studies will reveal the maximum dose of nitroprusside that can safely be metabolized in a 24-hour period, and may indicate that cofactors of rhodanase such as thiosulfate, or cobalamins such as hydroxocobalamin, can be administered with nitroprusside to prevent cyanide poisoning.
D000768:Anesthesia, General; D000818:Animals; D003486:Cyanides / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005292:Ferricyanides / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007023:Hypotension, Controlled; D008658:Inactivation, Metabolic; D009203:Myocardial Infarction / Q000188:drug therapy; D009599:Nitroprusside / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D011485:Protein Binding; D011955:Receptors, Drug; D013861:Thiocyanates / Q000097:blood; D014666:Vasomotor System / Q000187:drug effects
D003486:Cyanides; D005292:Ferricyanides; D011955:Receptors, Drug; D013861:Thiocyanates; D009599:Nitroprusside